Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

Presentation TCT 2025

Clinical Practice Response

Presenter: Usman Baber

October 28, 2025

Presentation TCT 2025

What’s New in the 2025 NSTEMI Guidelines

Presenter: Usman Baber

October 27, 2025

Presentation TCT 2025

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

Presenter: Usman Baber

October 26, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation TCT 2023

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Presenter: Usman Baber

October 23, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

Presentation TCT 2022

PCI in Patients With AF: The Risk and Benefit of Antithrombotic Therapy

Presenter: Usman Baber

September 18, 2022

News Daily News

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

Todd Neale

August 19, 2022

News Daily News

Heavy Calcification Levels PCI/CABG Playing Field at 10 Years: SYNTAXES

Yael L. Maxwell

January 06, 2022

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

Podcast TCTMD Talking Points

TWILIGHT: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

July 01, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Presentation TCT 2019

The Case for Long-Term (1 Year+) DAPT

Presenter: Usman Baber

September 27, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Advertisement

Clinical Practice Response

What’s New in the 2025 NSTEMI Guidelines

Antithrombotic Therapies in ACS: Atrial Fibrillation - Triple Therapy, Triple Threat!

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

PCI in Patients With AF: The Risk and Benefit of Antithrombotic Therapy

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

Heavy Calcification Levels PCI/CABG Playing Field at 10 Years: SYNTAXES

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

TWILIGHT: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

The Case for Long-Term (1 Year+) DAPT

TWILIGHT: A Deep Dive

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content